

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE 2023 P1134R2C4 10/688,132 10/17/2003 Avi J. Ashkenazi **EXAMINER** 05/22/2006 9157 7590 KAUFMAN, CLAIRE M GENENTECH, INC. 1 DNA WAY PAPER NUMBER ART UNIT SOUTH SAN FRANCISCO, CA 94080

1646 DATE MAILED: 05/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary	10/688,132	ASHKENAZI ET AL.
	Examiner	Art Unit
	Claire M. Kaufman	1646
The MAILING DATE of this communicati Period for Reply	on appears on the cover sheet wit	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR WHICHEVER IS LONGER, FROM THE MAILI - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica - If NO period for reply is specified above, the maximum statutor - Failure to reply within the set or extended period for reply will, be Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS COMMUNIC CFR 1.136(a). In no event, however, may a re tion. period will apply and will expire SIX (6) MONT y statute, cause the application to become ABA	CATION. ply be timely filed I'HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
1)⊠ Responsive to communication(s) filed or	17 October 2003.	
·= · · _	This action is non-final.	
3) Since this application is in condition for a	allowance except for formal matte	ers, prosecution as to the merits is
closed in accordance with the practice u	nder <i>Ex par</i> te <i>Quayle</i> , 1935 C.D.	11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) 65 and 67-93 is/are pending in	the application.	·
4a) Of the above claim(s) is/are w	thdrawn from consideration.	
5) Claim(s) is/are allowed.		
6)☐ Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8)⊠ Claim(s) <u>65, 67-93</u> are subject to restrict	ion and/or election requirement.	
Application Papers		
9)☐ The specification is objected to by the Ex	aminer.	
10) The drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to b	y the Examiner.
Applicant may not request that any objection	to the drawing(s) be held in abeyand	ce. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the	correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by	the Examiner. Note the attached	Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for for	oreign priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docu		
2. Certified copies of the priority docu		
3. Copies of the certified copies of th	•	received in this National Stage
application from the International E	• • • • • • • • • • • • • • • • • • • •	annived.
* See the attached detailed Office action for	a list of the certified copies flot f	
Attachment(s)		
1) Notice of References Cited (PTO-892)		ummary (PTO-413)
2) D Notice of Draftsperson's Patent Drawing Review (PTO-9	48) Paper No(s)	/Mail Date formal Patent Application (PTO-152)
 Information Disclosure Statement(s) (PTO-1449 or PTO/ Paper No(s)/Mail Date 	SB/08) 5) Notice of init	_·

Application/Control Number: 10/688,132

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

This application contains claims directed to the following patentably distinct species: treatment of the following conditions: T-cell mediated immune response, an inflammatory disease or disorder (including inflammation), autoimmune disease or disorder, graft vs. host disease, and allergy or asthma. The species are independent or distinct because each is caused by a different mechanism, involves distinct tissues or cells and consideration of disease type affects mode and manner of treatment.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

A telephone call was made to Diane Marschang on May 11, 2006, to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the

Application/Control Number: 10/688,132

Art Unit: 1646

inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571) 272-0873. Dr. Kaufman can generally be reached Monday, Tuesday, Thursday and Friday from 9:30AM to 2:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached at (571) 272-0835.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Official papers filed by fax should be directed to (571) 273-8300. NOTE: If applicant does submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Claire M. Kaufman, Ph.D.

Patent Examiner, Art Unit 1646

May 12, 2006 Clau M by